Literature DB >> 23859405

DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications.

Pallavi Shukla1, Avani Solanki, Kanjaksha Ghosh, Babu Rao Vundinti.   

Abstract

Interstrand cross-links (ICLs) are extremely toxic DNA lesions that prevent DNA double-helix separation due to the irreversible covalent linkage binding of some agents on DNA strands. Agents that induce these ICLs are thus widely used as chemotherapeutic drugs but may also lead to tumor growth. Fanconi anemia (FA) is a rare genetic disorder that leads to ICL sensitivity. This review provides update on current understanding of the role of FA proteins in repairing ICLs at various stages of cell cycle. We also discuss link between DNA cross-link genotoxicity caused by aldehydes in FA pathway. Besides this, we summarize various ICL agents that act as drugs to treat different types of tumors and highlight strategies for modulating ICL sensitivity for therapeutic interventions that may be helpful in controlling cancer and life-threatening disease, FA.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Fanconi anemia; cancer; chemotherapy; interstrand cross-links

Mesh:

Substances:

Year:  2013        PMID: 23859405     DOI: 10.1111/ejh.12169

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  FANCI is a negative regulator of Akt activation.

Authors:  Xiaoshan Zhang; Xiaoyan Lu; Shamima Akhter; Maria-Magdalena Georgescu; Randy J Legerski
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

2.  Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.

Authors:  Ping Chen; Jian Li; He-Guo Jiang; Ting Lan; Yong-Chang Chen
Journal:  Tumour Biol       Date:  2014-12-27

3.  CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.

Authors:  Chi-Che Hsieh; Sen-Huei Hsu; Chih-Yu Lin; Hung-Jiun Liaw; Ting-Wei Li; Kuan-Ying Jiang; Nai-Jung Chiang; Shang-Hung Chen; Bo-Wen Lin; Po-Chuan Chen; Ren-Hao Chan; Peng-Chan Lin; Yu-Min Yeh; Che-Hung Shen
Journal:  Br J Cancer       Date:  2022-08-23       Impact factor: 9.075

4.  Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers.

Authors:  Adel Alblihy; Reem Ali; Mashael Algethami; Ahmed Shoqafi; Michael S Toss; Juliette Brownlie; Natalie J Tatum; Ian Hickson; Paloma Ordonez Moran; Anna Grabowska; Jennie N Jeyapalan; Nigel P Mongan; Emad A Rakha; Srinivasan Madhusudan
Journal:  NPJ Precis Oncol       Date:  2022-07-19

5.  C17orf53 is identified as a novel gene involved in inter-strand crosslink repair.

Authors:  Chao Wang; Zhen Chen; Dan Su; Mengfan Tang; Litong Nie; Huimin Zhang; Xu Feng; Rui Wang; Xi Shen; Mrinal Srivastava; Megan E McLaughlin; Traver Hart; Lei Li; Junjie Chen
Journal:  DNA Repair (Amst)       Date:  2020-08-15

6.  A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non-Small Cell Lung Cancer Cells.

Authors:  Chi-Wei Chen; Ming-Hsi Wu; Yi-Fan Chen; Tsai-Yi Yen; Yi-Wen Lin; Shu-Hsin Chao; Satishkumar Tala; Tung-Hu Tsai; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2016-03-22       Impact factor: 5.715

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.